# Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients

> **NCT04121455** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **TME Pharma AG** · enrollment: 117 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Olaptesed pegol
- **RADIATION:** Radiotherapy
- **DRUG:** Bevacizumab
- **DRUG:** Pembrolizumab
- **DRUG:** Temozolomide (TMZ)

## Key facts

- **NCT ID:** NCT04121455
- **Lead sponsor:** TME Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-12
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04121455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04121455, "Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04121455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*